← Back to patent-cliff list
紫杉醇
Tier C — Watch / tradePaclitaxel
美国国立卫生研究院
Originator
1992
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：Tubulin
Brand：Genetaxyl、Taxol、Xorane、Paxene、Onxal、Padexol、Paxceed、Genaxol、OncoGel、Apealea、Nanotaxel、Genexol、Paclical、Pacligel、Yewtaxan、NanoPac、Paxoral (oral formulation)、Anzatax、Nanotax
Indications (approved)：胰腺癌、非小细胞肺癌、霍奇金病、精原细胞瘤、卵巢癌、乳腺癌、食道癌、头颈癌
Regional status
US
批准上市
1992-12-29
EU
临床三期
2004-07-01
China
批准上市
1996-01-01
Japan
无进展
2005-06-30
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Paclitaxel?
Approved indications include: 胰腺癌, 非小细胞肺癌, 霍奇金病, 精原细胞瘤, 卵巢癌, 乳腺癌, 食道癌, 头颈癌.
When does the Paclitaxel patent expire?
No public expiry year is available for Paclitaxel yet; this page updates once verified.
How do I get a quote for Paclitaxel intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25